- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04603248
A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
A study for identification of immune determinants for response to Nivolumab in Recurrent /Metastatic HNSCC(Head and neck squamous cell carcinoma) patients.
Recurrent and metastatic head and neck squamous cell carcinoma is incurable and requires aggressive treatment, resulting in functional disability, dismal prognosis, and high mortality rate. Prognosis of Recurrent and metastatic head and neck squamous cell carcinoma is poor, with limited treatment options and survival rates of 6-9 months following standard-of-care (SOC) therapies. Clinical trials have demonstrated promising clinical activity of anti PD-1(programmed death-1) therapy in head and neck squamous cell carcinoma. Currently, nivolumab were approved for head and neck squamous cell carcinoma refractory to platinum-based therapy. However, the response rate of anti PD-1(programmed death-1) therapy is relatively low and durable clinical benefit is limited to the minority of patients. Moreover, the presence of PD-1(programmed death-1) did not clearly predict response and treatment survival outcome, reflecting imperfection of this biomarker. Actually, PD-1(programmed death-1) negativity cannot preclude the therapeutic benefit of PD-1(programmed death-1) blockade, and vice versa. Hence, development of reliable predictive biomarkers is essential for proper patient selection to maximize clinical benefit of PD-1(programmed death-1) blockade in head and neck squamous cell carcinoma patients.
Therefore, we need to select patients who are most likely to benefit from anti PD-1(programmed death-1) therapy and identify the better biomarker to predict the response to PD-1(programmed death-1) blockade in head and neck squamous cell carcinoma patients. patients earlier than tumor assessment by imaging scan.
In the current study, we aimed to elucidate immune-related biomarkers to predict response with tumor tissue and peripheral blood from Recurrent /Metastatic HNSCC(Head and neck squamous cell carcinoma) patients treated with nivolumab.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Yonsei Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Sex: Male or female
- Age (at the time of informed consent): 19 years and older
- Subjects with histologically- or cytologically-confirmed recurrent and/or metastatic head and neck squamous cell carcinoma (Recurrent/Metastatic HNSCC)
- Known human papilloma virus (HPV) infection status with p16 immunohistochemistry or HPV in-situ hybridization
- Failed or intolerable to previous platinum-based chemotherapy
Patients who have at least 1 measurable or non-measurable lesion per the RECIST (Response Evaluation Criteria in Solid Tumor) Guideline Ver. 1.1 as confirmed by imaging within 28 days before enrollment. The following requirements should also be satisfied:
- If patients only have lesions that were previously treated with radiation, the lesion should be limited to one with confirmed aggravation by imaging after radiation.
- If patients have pericardial or pleural effusion or ascites only, the lesion should be limited to one with cytologically confirmed malignancy.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- Patients with a life expectancy of at least 3 months
Screening laboratory values within the specified ranges stated below, obtained within 14 days prior to first dose:
- White blood cells ≥2,000/mm3 and neutrophils ≥1,500/mm3
- Platelets ≥100,000/mm3
- Hemoglobin ≥9.0 g/dL
- AST (GOT) and ALT (GPT) ≤3.0-fold the upper limit of normal (ULN) of the study site (or ≤5.0-fold the ULN of the study site in patients with liver metastases)
- Total bilirubin ≤1.5-fold the ULN of the study site
- Creatinine ≤1.5-fold the ULN of the study site or creatinine clearance (either the measured or estimated value using the Cockcroft-Gault equation) >45 mL/min
- Explicit and voluntary consent to participate in the study obtained using a signed and dated informed consent form clearly and fully describing the purpose, potential risks, and any other critical issues regarding the study
- Women of childbearing potential (including women with chemical menopause or no menstruation for other medical reasons#1) must agree to use contraception(#2) from the time of informed consent until 5 months or more after the last dose of the investigational product. Also, women must agree not to breastfeed from the time of informed consent until 5 months or more after the last dose of the investigational product
Men must agree to use contraception(#2) from the start of study treatment until 7 months or more after the last dose of the investigational product.
- #1 Women of childbearing potential are defined as all women after the onset of menstruation who are not postmenopausal and have not been surgically sterilized (e.g., hysterectomy, bilateral tubal ligation, bilateral oophorectomy). Postmenopause is defined as amenorrhea for ≥12 consecutive months without specific reasons. Women using oral contraceptives, intrauterine devices, or mechanical contraception such as contraceptive barriers are regarded as having childbearing potential.
- #2 The subject must consent to use any two of the following methods of contraception: vasectomy or condom for patients who are male or female subject's partner and tubal ligation, contraceptive diaphragm, intrauterine device, spermicide, or oral contraceptive for patients who are female or male subject's partner.
Exclusion Criteria:
- Patients with multiple primary cancers (with the exception of completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer, or any other cancer that has not recurred for at least 3 years)
- Patients with residual adverse effects of prior therapy or effects of surgery that would affect the safety evaluation of the investigational product in the opinion of the investigator or sub-investigator.
- Patients with current or past history of severe hypersensitivity to any other antibody products
- Patients with concurrent autoimmune disease or history of chronic or recurrent autoimmune disease
- Patients with a current or past history of interstitial lung disease or pulmonary fibrosis diagnosed based on imaging or clinical findings. Patients with radiation pneumonitis may be enrolled if the radiation pneumonitis has been confirmed as stable (beyond acute phase) without any concerns about recurrence.
- Patients with concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease
- Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment. Patients may be enrolled if the metastasis is asymptomatic and requires no treatment.
- Patients with pericardial fluid, pleural effusion, or ascites requiring treatment
- Patients with uncontrollable, tumor-related pain
- Patients who have experienced medically refractory transient ischemic attack, cerebrovascular accident, thrombosis, or thromboembolism (pulmonary arterial embolism or deep vein thrombosis) within 180 days before enrollment
Patients with a history of uncontrollable or significant cardiovascular disease meeting any of the following criteria:
- Myocardial infarction within 180 days before enrollment
- Uncontrollable angina pectoris within 180 days before enrollment
- New York Heart Association (NYHA) Class III or IV congestive heart failure
- Uncontrollable hypertension despite appropriate treatment (e.g., systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥ 90 mmHg lasting 24 hours or more)
- Arrhythmia requiring treatment
- Patients with uncontrollable diabetes mellitus
- Patients with systemic infections requiring treatment with intravenous antibiotics
- Patients who have received systemic corticosteroids (more than 10mg/day prednisolone except for temporary use, e.g., for examination or prophylaxis of allergic reactions) or immunosuppressants within 28 days before enrollment
- Patients who have received antineoplastic drugs (e.g., chemotherapy agents, molecular-targeted therapy agents, or immunotherapy agents) within 14 days before enrollment
- Patients who have undergone surgical adhesion of the pleura or pericardium within 14 days before enrollment
- Patients who have undergone surgery under general anesthesia within 14 days before enrollment
- Patients who have undergone surgery involving local or topical anesthesia within 7 days before enrollment
- Patients who have received radiotherapy within 14 days before enrollment, or radiotherapy to bone metastases within 7 days before enrollment
- Patients who have received any radiopharmaceuticals (except for examination or diagnostic use of radiopharmaceuticals) within 56 days before enrollment
- Patients with a positive test result for any of the following: HIV-1 antibody, HIV-2 antibody, HTLV-1 antibody, HBs antigen, or HCV antibody
- Patients with a negative HBs antigen test but a positive test result for either HBs antibody or HBc antibody with a detectable level of HBV-DNA
- Women who are pregnant or breastfeeding, or possibly pregnant
- Patients who have received any other unapproved drug (e.g., investigational use of drugs, unapproved combined formulations, or unapproved dosage forms) within 28 days before enrollment
- Patients who have previously received Nivolumab, anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody or other therapeutic antibodies or pharmacotherapies for regulation of T-cells
- Patients judged to be incapable of providing consent for reasons such as concurrent dementia
- Other patients judged by the investigator or sub-investigator to be inappropriate as subjects of this study
- Patient with current or past history of hypersensitivity to Nivolumab.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
|
Nivolumab 3mg/kg treatment will be given every 2 weeks up to progression or unacceptable toxicity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Explore the biomarkers to predict objective response (OR)
Time Frame: Screening
|
Single cell RNA sequencing (scRNA-seq), Multiplex IHC (Vectra Polaris®), T cell immunophenotyping using flow cytometry, papilloma virus (HPV) infection status with p16 immunohistochemistry or HPV in-situ hybridization, Microbiome, Evaluation of PD-L1 expression status based on combined positivity score and tumor rate score
|
Screening
|
Explore the biomarkers to predict objective response (OR)
Time Frame: Before Cycle2 Day1 (each cycle is 14 days)
|
Single cell RNA sequencing (scRNA-seq), Multiplex IHC (Vectra Polaris®), T cell immunophenotyping using flow cytometry, papilloma virus (HPV) infection status with p16 immunohistochemistry or HPV in-situ hybridization, Evaluation of PD-L1 expression status based on combined positivity score and tumor rate score
|
Before Cycle2 Day1 (each cycle is 14 days)
|
Explore the biomarkers to predict objective response (OR)
Time Frame: From date of randomization until the date of first documented progression or date of unacceptable toxicity, whichever came first, assessed up to 100 months
|
Single cell RNA sequencing (scRNA-seq), Multiplex IHC (Vectra Polaris®), T cell immunophenotyping using flow cytometry, papilloma virus (HPV) infection status with p16 immunohistochemistry or HPV in-situ hybridization, Evaluation of PD-L1 expression status based on combined positivity score and tumor rate score
|
From date of randomization until the date of first documented progression or date of unacceptable toxicity, whichever came first, assessed up to 100 months
|
Explore the biomarkers to predict progression-free survival (PFS)
Time Frame: Screening
|
Single cell RNA sequencing (scRNA-seq), Multiplex IHC (Vectra Polaris®), T cell immunophenotyping using flow cytometry, papilloma virus (HPV) infection status with p16 immunohistochemistry or HPV in-situ hybridization, Microbiome, Evaluation of PD-L1 expression status based on combined positivity score and tumor rate score
|
Screening
|
Explore the biomarkers to predict progression-free survival (PFS)
Time Frame: Before Cycle2 Day1 (each cycle is 14 days)
|
Single cell RNA sequencing (scRNA-seq), Multiplex IHC (Vectra Polaris®), T cell immunophenotyping using flow cytometry, papilloma virus (HPV) infection status with p16 immunohistochemistry or HPV in-situ hybridization, Evaluation of PD-L1 expression status based on combined positivity score and tumor rate score
|
Before Cycle2 Day1 (each cycle is 14 days)
|
Explore the biomarkers to predict progression-free survival (PFS)
Time Frame: From date of randomization until the date of first documented progression or date of unacceptable toxicity, whichever came first, assessed up to 100 months
|
Single cell RNA sequencing (scRNA-seq), Multiplex IHC (Vectra Polaris®), T cell immunophenotyping using flow cytometry, papilloma virus (HPV) infection status with p16 immunohistochemistry or HPV in-situ hybridization, Evaluation of PD-L1 expression status based on combined positivity score and tumor rate score
|
From date of randomization until the date of first documented progression or date of unacceptable toxicity, whichever came first, assessed up to 100 months
|
Explore the biomarkers to predict overall survival (OS)
Time Frame: Screening
|
Single cell RNA sequencing (scRNA-seq), Multiplex IHC (Vectra Polaris®), T cell immunophenotyping using flow cytometry, papilloma virus (HPV) infection status with p16 immunohistochemistry or HPV in-situ hybridization, Microbiome, Evaluation of PD-L1 expression status based on combined positivity score and tumor rate score
|
Screening
|
Explore the biomarkers to predict overall survival (OS)
Time Frame: Before Cycle2 Day1 (each cycle is 14 days)
|
Single cell RNA sequencing (scRNA-seq), Multiplex IHC (Vectra Polaris®), T cell immunophenotyping using flow cytometry, papilloma virus (HPV) infection status with p16 immunohistochemistry or HPV in-situ hybridization, Evaluation of PD-L1 expression status based on combined positivity score and tumor rate score
|
Before Cycle2 Day1 (each cycle is 14 days)
|
Explore the biomarkers to predict overall survival (OS)
Time Frame: From date of randomization until the date of first documented progression or date of unacceptable toxicity, whichever came first, assessed up to 100 months
|
Single cell RNA sequencing (scRNA-seq), Multiplex IHC (Vectra Polaris®), T cell immunophenotyping using flow cytometry, papilloma virus (HPV) infection status with p16 immunohistochemistry or HPV in-situ hybridization, Evaluation of PD-L1 expression status based on combined positivity score and tumor rate score
|
From date of randomization until the date of first documented progression or date of unacceptable toxicity, whichever came first, assessed up to 100 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Number of participants with adverse events and abnormal laboratory values as assessed by NCI-CTCAE version 5
Time Frame: From date of randomization until the date of first documented progression or date of unacceptable toxicity, whichever came first, assessed up to 100 months
|
Number of participants with adverse events and abnormal laboratory values as assessed by NCI-CTCAE version 5
|
From date of randomization until the date of first documented progression or date of unacceptable toxicity, whichever came first, assessed up to 100 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hye Ryun Kim, Severance Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Carcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- 4-2020-0801
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Squamous Cell Carcinoma (HNSCC)
-
RTOG Foundation, Inc.Bristol-Myers SquibbCompletedHead and Neck Squamous Cell Carcinoma (HNSCC)United States
-
Centre Antoine LacassagneGERCOR - Multidisciplinary Oncology Cooperative Group; GORTECWithdrawnHead and Neck Squamous Cell Carcinoma (HNSCC)France
-
Icahn School of Medicine at Mount SinaiRecruitingHead and Neck Squamous Cell Carcinoma (HNSCC)United States
-
Navidea BiopharmaceuticalsTerminatedHead and Neck Squamous Cell Carcinoma (HNSCC)United States
-
Memorial Sloan Kettering Cancer CenterCompletedHead and Neck Squamous Cell Carcinoma (HNSCC)United States
-
Robert FerrisImmune Cell Therapy Inc.WithdrawnHead and Neck Squamous Cell Carcinoma (HNSCC)United States
-
Robert L. Ferris, MD, PhDBristol-Myers SquibbRecruitingHead and Neck Squamous Cell Carcinoma (HNSCC)United States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | HNSCC | Head Cancer Neck
-
Memorial Sloan Kettering Cancer CenterRegeneron PharmaceuticalsRecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | HNSCC | Head Cancer | Neck Cancer | Head Cancer NeckUnited States
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruiting
Clinical Trials on Nivolumab
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...Terminated
-
Bristol-Myers SquibbRecruitingMelanomaSpain, United States, Italy, Chile, Greece, Argentina
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
HUYABIO International, LLC.Bristol-Myers SquibbRecruitingUnresectable or Metastatic Melanoma | Progressive Brain MetastasisSpain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingAdvanced Renal Cell CarcinomaUnited States
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
-
IRCCS San RaffaeleBristol-Myers SquibbRecruiting
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan